Search

Tausif N Alam

from Madison, WI
Age ~71
Get Report
Also known as:
Alam Tausif
Phone and address:
6 Essex Ct, Madison, WI 53713
(608) 270-0246
Related to:
Imran Alam Khan, 36Asif A Khan, 33Heidi Walters Khan, 66
Connected to:
Abbas S Alam, 39Abdullah Alam, 39Akil A Alam, 40Akm K Alam, 55Alam K Alam, 57Alamgir Alam, 53Andrea J Alam, 54Arshad Alam, 49Asrar Alam, 54Atikul D Alam, 49

Tausif Alam Phones & Addresses

  • 6 Essex Ct, Madison, WI 53713 (608) 270-0246 (608) 270-0948
  • 1 University Houses, Madison, WI 53705
  • Duncanville, TX
  • Madison, OH
  • 6 Essex Ct, Madison, WI 53713 (608) 843-1266

Work

Position: Construction and Extraction Occupations

Education

Degree: High school graduate or higher

Emails

d***[email protected]

Resumes

Resumes

Tausif Alam Photo 1

Scientist

View page
Location:
Madison, WI
Industry:
Hospital & Health Care
Work:
University of Wisconsin-Madison
Scientist
University of Wisconsin Department of Surgery
Scientist
Education:
Chatrapati Sahuji Maharaj Kanpur University, Kanpur 1973 - 1978
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Molecular Biology
Cell Biology
Western Blotting
Pcr
Cell Culture
Genetics
Type 1 Diabetes
Gene Therapy
Hepatocytes
Hepatocyte Derivation From Hes and Ips Cells
Animal Models of Type 1 Diabetes
Survival Surgery and Management of Animal Model of Type 1 Diabetes
Interests:
Children
Education
Environment
Science and Technology
Human Rights
Health
Tausif Alam Photo 2

Tausif Alam

View page
Tausif Alam Photo 3

Tausif Alam

View page
Tausif Alam Photo 4

Tausif Alam

View page
Tausif Alam Photo 5

Tausif Alam

View page

Publications

Us Patents

Treatment Of Diabetes With Synthetic Beta Cells

View page
US Patent:
6933133, Aug 23, 2005
Filed:
Nov 12, 2001
Appl. No.:
10/013032
Inventors:
Tausif Alam - Madison WI, US
Debra A. Hullett - Madison WI, US
Hans W. Sollinger - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12P021/04
C12P021/06
C12N015/74
C12N015/87
C12N005/00
C12N048/00
US Classification:
435 691, 435 696, 4353201, 435325, 435455, 514 44, 424 932, 424 9321
Abstract:
Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Treatment Of Diabetes With Synthetic Beta Cells

View page
US Patent:
7425443, Sep 16, 2008
Filed:
May 12, 2005
Appl. No.:
11/127629
Inventors:
Tausif Alam - Madison WI, US
Debra A. Hullett - Madison WI, US
Hans W. Sollinger - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12N 15/00
A01N 63/00
US Classification:
4353201, 424 932, 424 9321, 536 235, 536 241
Abstract:
Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Treatment Of Diabetes With Synthetic Beta Cells

View page
US Patent:
20070280908, Dec 6, 2007
Filed:
Aug 23, 2004
Appl. No.:
10/923924
Inventors:
Tausif Alam - Madison WI, US
Debra Hullett - Madison WI, US
Hans Sollinger - Madison WI, US
International Classification:
A61K 35/76
A61K 31/7052
A61P 3/08
C12N 15/63
C12N 15/86
C12N 5/08
C12N 7/01
US Classification:
424093600, 435235100, 435320100, 435370000, 435455000, 435456000, 514044000
Abstract:
Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

Hepatocyte Based Insulin Gene Therapy For Diabetes

View page
US Patent:
20120315255, Dec 13, 2012
Filed:
Jun 6, 2012
Appl. No.:
13/490081
Inventors:
Tausif Alam - Madison WI, US
Hans Sollinger - Madison WI, US
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
A61K 31/7088
A61P 3/10
A61K 35/407
C12N 15/85
C12N 15/86
US Classification:
424 9321, 435455, 435456, 4353201, 514 44 R
Abstract:
A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled.

Treatment Of Diabetes With Synthetic Beta Cells

View page
US Patent:
6352857, Mar 5, 2002
Filed:
Mar 28, 2000
Appl. No.:
09/537696
Inventors:
Tausif Alam - Madison WI
Debra A. Hullett - Madison WI
Hans W. Sollinger - Madison WI
Assignee:
Wisconsin Alumni Research Foundation - Madison WI
International Classification:
C12N 1500
US Classification:
4353201, 536 241, 536 235
Abstract:
Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose responsive regulatory module having at least one glucose inducible regulatory element comprising a pair of CACGTG motifs linked by a five base nucleotide sequence, which confers glucose inducible expression of the proinsulin coding sequence. To ensure proper processing of the proinsulin to active insulin, the coding sequence was modified to direct the synthesis of a mutant proinsulin polypeptide having amino acid sequences that can be cleaved to mature insulin in suitable host cells, such as hepatocytes.

In Vivo Gene Therapy Delivery Procedure And Device

View page
US Patent:
20230074581, Mar 9, 2023
Filed:
Nov 15, 2022
Appl. No.:
17/987578
Inventors:
- Madison WI, US
Erik Aiken - Madison WI, US
John Booske - McFarland WI, US
Hans Sollinger - Madison WI, US
Paul Laeseke - Madison WI, US
Tausif Alam - Madison WI, US
International Classification:
A61N 1/32
A61M 25/10
A61K 48/00
Abstract:
A “localizable” systemic gene therapy system is provided substantially increasing the transfection efficiency of the gene vectors into targeted tissue cells and substantially reducing the escape of the gene vectors from the targeted tissue volume, such as would waste the vectors, promote undesired immune reactions, and/or incur prohibitive costs for the required dose of gene-containing virus vectors. In this regard, the invention provides a means to simultaneously achieve local electroporation and gene-containing vector injection in a portion of a vascularized organ. It includes two double-balloon catheters that create contained volumes in parallel blood vessels for the introduction of vectors with reduced loss along with electrodes providing electroporation of the cells in the same location where the vectors are injected.

In Vivo Gene Therapy Delivery Procedure And Device

View page
US Patent:
20210146127, May 20, 2021
Filed:
Jan 28, 2021
Appl. No.:
17/160832
Inventors:
- Madison WI, US
Erik Aiken - Madison WI, US
John Booske - McFarland WI, US
Hans Sollinger - Madison WI, US
Paul Laeseke - Madison WI, US
Tausif Alam - Madison WI, US
International Classification:
A61N 1/32
A61M 25/10
A61K 48/00
Abstract:
A “localizable” systemic gene therapy system is provided substantially increasing the transfection efficiency of the gene vectors into targeted tissue cells and substantially reducing the escape of the gene vectors from the targeted tissue volume, such as would waste the vectors, promote undesired immune reactions, and/or incur prohibitive costs for the required dose of gene-containing virus vectors. In this regard, the invention provides a means to simultaneously achieve local electroporation and gene-containing vector injection in a portion of a vascularized organ. It includes two double-balloon catheters that create contained volumes in parallel blood vessels for the introduction of vectors with reduced loss along with electrodes providing electroporation of the cells in the same location where the vectors are injected.

In Vivo Gene Therapy Delivery Procedure And Device

View page
US Patent:
20200030602, Jan 30, 2020
Filed:
Jul 24, 2018
Appl. No.:
16/043461
Inventors:
- Madison WI, US
Erik Aiken - Madison WI, US
John Booske - McFarland WI, US
Hans Sollinger - Madison WI, US
Paul Laeseke - Madison WI, US
Tausif Alam - Madison WI, US
International Classification:
A61N 1/32
A61M 25/10
A61K 48/00
Abstract:
A “localizable” systemic gene therapy system is provided substantially increasing the transfection efficiency of the gene vectors into targeted tissue cells and substantially reducing the escape of the gene vectors from the targeted tissue volume, such as would waste the vectors, promote undesired immune reactions, and/or incur prohibitive costs for the required dose of gene-containing virus vectors. In this regard, the invention provides a means to simultaneously achieve local electroporation and gene-containing vector injection in a portion of a vascularized organ. It includes two double-balloon catheters that create contained volumes in parallel blood vessels for the introduction of vectors with reduced loss along with electrodes providing electroporation of the cells in the same location where the vectors are injected.
Control profile
Tausif N Alam from Madison, WI, age ~71 Get Report